Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

1.

Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial.

Ehlken N, Lichtblau M, Klose H, Weidenhammer J, Fischer C, Nechwatal R, Uiker S, Halank M, Olsson K, Seeger W, Gall H, Rosenkranz S, Wilkens H, Mertens D, Seyfarth HJ, Opitz C, Ulrich S, Egenlauf B, Grünig E.

Eur Heart J. 2015 Jul 31. pii: ehv337. [Epub ahead of print]

PMID:
26231884
2.

Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.

Ghofrani HA, Staehler G, Grünig E, Halank M, Mitrovic V, Unger S, Mueck W, Frey R, Grimminger F, Schermuly RT, Behr J.

Pulm Circ. 2015 Jun;5(2):296-304. doi: 10.1086/680214.

3.

Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Marra AM, Egenlauf B, Ehlken N, Fischer C, Eichstaedt C, Nagel C, Bossone E, Cittadini A, Halank M, Gall H, Olsson KM, Lange TJ, Grünig E.

Int J Cardiol. 2015 Sep 15;195:19-26. doi: 10.1016/j.ijcard.2015.05.105. Epub 2015 May 19.

4.

[Dyspnoea in Patients with Pulmonary Hypertension (PH) - a Survey in Spezialized German PH Centres].

Ewert R, Wilkens H, Skowasch D, Reppel M, Bollmann T, Halank M, Held M, Klose H, Gall H, Lange TJ, Opitz CF, Seyfarth HJ, Winkler J.

Pneumologie. 2015 Jun;69(6):361-5. doi: 10.1055/s-0034-1391893. Epub 2015 Apr 21. German.

PMID:
25962567
5.

[Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].

Leuchte HH, Behr J, Ewert R, Ghofrani HA, Grünig E, Halank M, Held M, Klose H, Rosenkranz S, Schermuly RT, Wilkens H, Hoeper MM.

Pneumologie. 2015 Mar;69(3):135-43. doi: 10.1055/s-0034-1391435. Epub 2015 Mar 6. German.

PMID:
25750094
6.

[Imatinib for pulmonary arterial hypertension].

Hoeper MM, Opitz C, Olschewski H, Ulrich S, Speich R, Behr J, Halank M, Wilkens H, Klose H, Lange TJ, Grünig E, Seeger W, Ewert R, Borst MM, Welte T, Rosenkranz S, Ghofrani HA.

Dtsch Med Wochenschr. 2014 Dec;139 Suppl 4:S151-4. doi: 10.1055/s-0034-1387457. Epub 2014 Dec 9. Review. German. No abstract available.

PMID:
25489685
7.

[Quality of life in pulmonal arterial hypertension and in chronic thromboembolic pulmonary hypertension].

Halank M, Speich R, Petkova D, Saxer S, Müller-Mottet S, Hasler E, Kolditz M, Wilkens H, Ehlken N, Lichtblau M, Egenlauf B, Kähler C, Lüneburg N, Mertens D, Schulz U, Barner A, Grünig E, Puhan M, Ulrich S.

Dtsch Med Wochenschr. 2014 Dec;139 Suppl 4:S126-35. doi: 10.1055/s-0034-1387482. Epub 2014 Dec 9. Review. German. No abstract available.

PMID:
25489682
8.

Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension.

Seyfarth HJ, Favreau N, Tennert C, Ruffert C, Halank M, Wirtz H, Mössner J, Rosendahl J, Kovacs P, Wittenburg H.

Ann Hepatol. 2014 Nov-Dec;13(6):803-9.

9.

Response to letters regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)".

Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Grünig E, Staehler G, Rosenkranz S, Halank M, Held M, Lange TJ, Behr J, Klose H, Claussen M, Ewert R, Opitz CF, Vizza CD, Scelsi L, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Coghlan G, Pepke-Zaba J, Schulz U, Gorenflo M, Pittrow D, Hoeper MM.

Circulation. 2014 Sep 16;130(12):e110-2. doi: 10.1161/CIRCULATIONAHA.114.010921. No abstract available.

PMID:
25223780
10.

Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.

Thomas K, Schrötter H, Halank M, Ziemssen T.

BMC Neurol. 2014 Jun 7;14:126. doi: 10.1186/1471-2377-14-126.

11.

Haemoptysis due to pulmonary venous stenosis.

Braun S, Platzek I, Zöphel K, Weise M, Kolditz M, Halank M, Hoeffken G.

Eur Respir Rev. 2014 Jun;23(132):170-9. doi: 10.1183/09059180.00003713. Review. Erratum in: Eur Respir Rev. 2014 Sep;23(133):399.

12.

Tobacco smoke exposure in pulmonary arterial and thromboembolic pulmonary hypertension.

Keusch S, Hildenbrand FF, Bollmann T, Halank M, Held M, Kaiser R, Kovacs G, Lange TJ, Seyfarth HJ, Speich R, Ulrich S.

Respiration. 2014;88(1):38-45. doi: 10.1159/000359972. Epub 2014 May 15.

PMID:
24853610
13.

Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertension.

Hennigs JK, Baumann HJ, Lüneburg N, Quast G, Harbaum L, Heyckendorf J, Sydow K, Schulte-Hubbert B, Halank M, Klose H.

Sci Rep. 2014 Apr 28;4:4808. doi: 10.1038/srep04808.

14.

Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.

Seyfarth HJ, Hammerschmidt S, Halank M, Neuhaus P, Wirtz HR.

Pulm Circ. 2013 Sep;3(3):632-8. doi: 10.1086/674311. Epub 2013 Nov 19.

15.

Economic evaluation of exercise training in patients with pulmonary hypertension.

Ehlken N, Verduyn C, Tiede H, Staehler G, Karger G, Nechwatal R, Opitz CF, Klose H, Wilkens H, Rosenkranz S, Halank M, Grünig E.

Lung. 2014 Jun;192(3):359-66. doi: 10.1007/s00408-014-9558-9. Epub 2014 Mar 8.

PMID:
24609926
16.

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Harzheim D, Klose H, Pinado FP, Ehlken N, Nagel C, Fischer C, Ghofrani A, Rosenkranz S, Seyfarth HJ, Halank M, Mayer E, Grünig E, Guth S.

Respir Res. 2013 Oct 9;14:104. doi: 10.1186/1465-9921-14-104.

17.

Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Grünig E, Staehler G, Rosenkranz S, Halank M, Held M, Lange TJ, Behr J, Klose H, Claussen M, Ewert R, Opitz CF, Vizza CD, Scelsi L, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Coghlan G, Pepke-Zaba J, Schulz U, Gorenflo M, Pittrow D, Hoeper MM.

Circulation. 2014 Jan 7;129(1):57-65. doi: 10.1161/CIRCULATIONAHA.113.004526. Epub 2013 Sep 30.

18.

Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.

Grünig E, Tiede H, Enyimayew EO, Ehlken N, Seyfarth HJ, Bossone E, D'Andrea A, Naeije R, Olschewski H, Ulrich S, Nagel C, Halank M, Fischer C.

Circulation. 2013 Oct 29;128(18):2005-15. doi: 10.1161/CIRCULATIONAHA.113.001573. Epub 2013 Sep 20.

19.

Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency.

Gläser S, Obst A, Koch B, Henkel B, Grieger A, Felix SB, Halank M, Bruch L, Bollmann T, Warnke C, Schäper C, Ewert R.

PLoS One. 2013 Jun 20;8(6):e65643. doi: 10.1371/journal.pone.0065643. Print 2013.

20.

Exercise capacity affects quality of life in patients with pulmonary hypertension.

Halank M, Einsle F, Lehman S, Bremer H, Ewert R, Wilkens H, Meyer FJ, Grünig E, Seyfarth HJ, Kolditz M, Wieder G, Höffken G, Köllner V.

Lung. 2013 Aug;191(4):337-43. doi: 10.1007/s00408-013-9472-6. Epub 2013 May 17.

PMID:
23681593
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk